Table 4 Total cohort tumor detection rates using imaging screening by history of prior PGL/PCC.

From: Tumor detection rates in screening of individuals with SDHx-related hereditary paraganglioma–pheochromocytoma syndrome

 

HCI

U of M

Penn

Total

Percent

Subjects without prior history of PGL/PCC, n

83

59

52

194

74% (194/263)

 Subjects with screen positive SDHx-related tumor, n

18

7

11

36

19% (36/194)

 Subjects with recurrence of SDHx-related tumor on screen, n

0

0

1

1

 

 Subjects with false positive screen for SDHx-related tumors, n

0

2

0

2

 

 Subjects with indeterminate finding for SDHx-related tumors, n

1

0

0

1

 

Subjects with prior history of PGL/PCC, n

17

36

16

69

26% (69/263)

 Subjects with screen positive SDHx-related tumor, n

6

1

2

9

13% (9/69)

 Subjects with recurrence of SDHx-related tumor on screen, n

1

0

1

2

 

 Subjects with false positive screen for SDHx-related tumors, n

0

2

0

2

 

 Subjects with indeterminate finding for SDHx-related tumors, n

0

1

0

1

 

Total subjects with positive screen for SDHx-related tumor, n

24

8

13

45

17% (45/263)

  1. HCI Huntsman Cancer Institute, PCC pheochromocytomas, Penn University of Pennsylvania, PGL paragangliomas, U of M University of Michigan.